Due to the variety of therapeutic options that are currently available for patients diagnosed with Barrett’s-related high-grade dysplasia (BE-HGD), the choice of optimal management continues to be a topic of discussion among gastroenterologists, surgeons, oncologists, pathologists, and patients.